Join CBMTG | Print Page | Contact Us | Sign In
Upcoming Webinars

 

The University of British Columbia Division of Continuing Professional Development (UBC CPD) is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME) to provide study credits for continuing medical education for physicians.  This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and has been approved by UBC CPD for up to 10.0 MOC Section 1 Group Learning credits. Each physician should claim only those credits he/she actually spent in the activity.


CBMTG 2019 Webinar Series Poster

To help promote the webinar series in your BMT centre please download the CBMTG 2019 Webinar Series Poster, here.

If you would like to receive a printed copy for your centre, please contact CBMTG Head Office.


Wednesday, April 10, 2019
9:00am PT/12:00pm ET
CME CREDIT HOURS: 1.0


Making Hematopoietic Stem Cell Donation Better for Canadians

David Allan, MD, FRCPC (Ottawa Hospital Research Institute, Ottawa, Ontario)


Brief Biography: 

Dr. David Allan is a hematologist with the Blood and Marrow Transplant Program at the Ottawa Hospital, and Associate Professor at the University of Ottawa. He is one of the Medical Directors in Stem Cells at Canadian Blood Services which includes an adult stem cell registry, a public umbilical cord blood bank, and manufacturing services for cell processing and storage. His research interests focus on translating cell-based regenerative therapies into clinical practice and working with the Blood and Marrow Transplant community to improve access to better donor options to support patients in need of hematopoietic cell transplantation.

Synopsis:
The webinar will address the current needs of Canadian patients who are candidates for hematopoietic cell transplantation and discuss optimal donor choices. We will explore potential barriers to finding optimal donors and highlight the impact of changes to improve donor options for Canadian patients.
 

Learning Objectives:

  1. List donor factors that impact transplant outcomes
  2. State the potential impact of improved HLA-match likelihoods for different ethnicities
  3. List potential new roles for stem cell registrants and banked cord blood units
     


Wednesday, May 22, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0


Drug Related Issues in BMT

Lee Dupuis, RPh, ACPR, FCSHP, PhD (Hospital for Sick Children, Toronto, Ontario)

Learning Objectives:
TBA


Wednesday, June 2019
TIME TBD
CME CREDIT HOURS: 1.0


Gynecological Issues Post-Transplant

Michelle Jacobson, MD (Women’s College Hospital, Mount Sinai, Toronto, Ontario)

Learning Objectives:
TBA



Wednesday, September 11, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Counting CD34+ Cells in the Clinical Transplantation Setting: Interesting Cases and Implications for Assessment of Graft Adequacy

D. Robert Sutherland, PhD, BSc, MSc (University of Toronto, Toronto, Ontario)

Speaker Biography:
Dr. Sutherland worked at the Imperial Cancer Research Fund in London before moving to the Toronto General Hospital in 1984. He became an Assistant Professor in 1989, Associate Professor in 1997, and Full Professor in the Dept. of Medicine University of Toronto in 2009. Dr. Sutherland’s work on CD34 led to the development of the ISHAGE Guidelines to enumerate CD34+ cells by flow cytometry. Until his recent retirement, Dr. Sutherland was the Technical Director of the Clinical Flow facility in the Toronto General Hospital (TGH) where he oversaw the development of new flow assays to detect rare blood disorders. Dr. Sutherland has published over one-hundred peer-reviewed articles, fifteen review articles, twelve editorials and eighteen technical monographs. 

Synopsis:
Cells in the bone marrow expressing the CD34 antigen are responsible for long-term engraftment in the BM transplant setting. Once mobilized into the circulation, CD34+ cells can be collected by apheresis and the engraftment potential of the collected cells assessed using flow cytometry to detect CD34+ cells. The ISHAGE protocol was developed to perform this task and technical aspects of its development and its deployment in the clinical flow laboratory will be detailed. Illustrative examples of analytic errors that can be occasionally encountered will also be discussed. 

Learning Objectives:
1. Determine why and how we count CD34+ cells
2. Review how to develop International Guidelines
3. Discuss the importance of Single Platform approaches
4. Summarize sample-related analytic errors based on illustrative cases



Wednesday, October 16, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Controversies in Use of High Dose Chemotherapy in Patients with Progressive Germ Cell Tumor Following Cisplatin-Based Combination Chemotherapy

Lawrence H. Einhorn, MD (Indiana University, Indianapolis, Indiana)

Learning Objectives:
1. Understand the rationale behind high dose chemotherapy with peripheral blood stem cell transplant
2. Appreciate the controversy of high dose versus standard dose salvage chemotherapy
3. Learn about managements of complications from high dose chemotherapy with peripheral blood stem cell rescue



Wednesday, November 6, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Integrating Chronic GvHD Biomarkers into the Clinical Evaluation of Chronic GvHD According to the National Institutes of Health Consensus Criteria

Geoff Cuvelier, MD, FRCPC (CancerCare Manitoba, Winnipeg, Manitoba)
 
Speaker Biography:
Dr. Geoff Cuvelier is the Director of Pediatric BMT within the Manitoba Blood and Marrow Transplant program at CancerCare Manitoba and Associate Professor of Pediatrics in the Max Rady Faculty of Health Sciences, Department of Pediatrics and Child and Health at the University of Manitoba.  Dr. Cuvelier has been the lead Co-PI for the multi-institutional Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) / Pediatric Blood and Marrow Transplant Consortium 1202 study that evaluated both the clinical evaluation of chronic GvHD in children, as well as prognostic cGvHD biomarkers used to predict which children are at higher risk for developing cGvHD.  
 
Synopsis:
In this talk, Dr. Cuvelier will discuss the evaluation of cGvHD according to the National Institutes of Health consensus criteria (applicable to both adults and children), the benefits and challenges with doing so in clinical practice, and how prognostic biomarkers present before the onset of cGvHD may be useful in the future in predicting which patients are at higher or lower risk for developing cGvHD.

 

Learning Objectives:
1. Have an appreciation for the National Institutes of Health Consensus Criteria (NIH-CC) for Chronic GvHD evaluation, including the difference between diagnostic, distinctive, common, and other manifestations of GVHD, and how these can be applied to the classification and evaluation of GvHD in clinical practice
2. Appreciate the benefits and challenges with the NIH-CC in evaluating cGvHD
3. Discuss how prognostic biomarkers may in the future be integrated into the risk assessment and evaluation of cGvHD

 

 


Wednesday, December 11, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0

Cellular Therapy Manufacturing – Clinical Trials and Hopes for the Future

David Courtman, MD (Ottawa Hospital Research Institute, Ottawa, Ontario)

Learning Objectives:
1. To gain an understanding of the regulatory requirements for clinical cell processing for products involving more than minimal manipulation or intended for non-homologous use.
2. Describe the infrastructure commonly used in cGMP manufacturing of experimental cell products.
3. Provide examples of clinical trial designs and outcome measures in advanced cell therapy trials.

 

This website is sponsored by an unrestricted educational grant from:

Follow CBMTG